Lilly Rises on Plan to Expand Medicare Weight-Loss Coverage (3)

Shares of Eli Lilly & Co. gained on a proposal for Medicaid and some Medicare drug plans to experiment with covering expensive weight-loss drugs, a sign the Trump administration is reconsidering its position against expanding coverage of these treatments.

US health officials are considering a pilot project that would allow the programs to cover GLP-1 drugs for obesity, according to people familiar with the matter who weren’t authorized to speak publicly. The test would begin in April 2026 for Medicaid and January 2027 for Medicare, but isn’t final and plans could change, according to the Washington Post, which originally ...